Long-term follow-up on berberine's effects on colorectal health
A Multicenter, Placebo-controlled Clinical Study of Berberine Hydrochloride in Preventing Recurrence and Carcinogenesis After Endoscopic Removal of Colorectal Adenomas：6-year Retrospective Follow-up Data
This study looks at whether taking berberine can help prevent the return of colorectal polyps and adenomas in people who have already tried it before.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 891 (estimated) |
| Sex | All |
| Sponsor | Shanghai Jiao Tong University School of Medicine Academic / other |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT06629051 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the long-term effects of berberine on patients who previously participated in a randomized controlled trial focused on colorectal adenoma and cancer prevention. The study will follow up with participants to evaluate the recurrence of colorectal polyps and adenomas after treatment with berberine hydrochloride compared to a placebo. The research builds on previous findings that indicated berberine significantly reduced the recurrence of colorectal adenomas. By analyzing data over a six-year period, the study seeks to provide insights into the sustained benefits of berberine as a chemopreventive agent.
Who should consider this trial
Good fit: Ideal candidates are individuals who completed the previous berberine intervention study (NCT02226185).
Not a fit: Patients who did not participate in the previous berberine intervention study may not benefit from this follow-up.
Why it matters
Potential benefit: If successful, this study could provide valuable evidence for the long-term effectiveness of berberine in preventing colorectal cancer recurrence.
How similar studies have performed: Previous studies have shown success with berberine in reducing colorectal adenoma recurrence, indicating a promising approach for this follow-up.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: participants who completed the previous berberine intervention study (NCT02226185) Exclusion Criteria: no
Where this trial is running
Shanghai
- Renji Hospital, Shanghai Jiao-Tong University School of Medicine — Shanghai, China (Recruiting)
Study contacts
- Principal investigator: Jing-Yuan Fang, M.D, Ph.D — RenJi Hospital
- Study coordinator: Jing-Yuan Fang, Professor
- Email: jingyuanfang@sjtu.edu.cn
- Phone: 021-13918386561
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.